Menopause

On March 18, President Joe Biden signed an executive order and announced new actions to improve women’s health research and innovation in the U.S., according to a White House press release.

Fezolinetant and elinzanetant are both promising nonhormone therapies for managing vasomotor symptoms among postmenopausal women, with favorable safety profiles for up to 12 weeks, according to a systematic review published in Menopause.

Once-daily oral elinzanetant was associated with significantly reduced frequency of moderate to severe menopausal vasomotor symptoms compared with placebo, according to topline results from the OASIS 3 study.

Black women tend to prefer to see Black obstetric providers during pregnancy due to past experiences of racism and discrimination, according to a presenter at The Pregnancy Meeting.

Healio has compiled a list of the top headlines in cardiology from February 2024.

A new at-home test promises the ability to indicate women’s stage in menopause, but some experts are skeptical about how useful the product actually is.

Curriculums that paired several podcast episodes with case-based classroom discussions improved preparation and knowledge on menopause among OB/GYN, family medicine and internal medicine specialists, researchers reported in Menopause.

A new at-home menopause test hit the market last fall, promising women the ability to accurately measure a hormone associated with menopause stage and predict how close they might be to their final menstrual period.

Migraine plus persistent vasomotor symptoms is associated with greater CVD risk and stroke for women, according to a secondary data analysis published in Menopause.

Age at menstruation, age at menopause, number of children, miscarriage and stillbirth each impacted a woman’s risk for COPD, according to results published in Thorax.